INTRODUCTION
Breast cancer is the most common malignancy among women worldwide. 1, 2 The prognosis of this disease mainly depends on its early detection, which currently to a major part relies on mammography. Early detection of this disease can also be facilitated by new diagnostic biomarkers 3 cell-free DNA (cfDNA) and circulating tumor cells (CTCs), released into the bloodstream by solid tumors, are considered real-time liquid biopsies in cancer patients reflecting the disease complexity and progression. The liquid biopsy represents a surrogate material for the molecular characterization of solid cancers. 4 In fact, in the advanced stages when the tumor has acquired genetic, epigenetic and expression features which may be very different from those of the primary tissue, the liquid biopsy represents the actual molecular signature of the disease. Total cfDNA concentration, higher in cancer patients than healthy individuals, 5 has been proposed as a cancer marker, but it has shown limited sensitivity and specificity. .6,7 DNA methylation acts as a major epigenetic mechanism within the complex network of mechanisms regulating gene expression. 8 The chemically stable addition of a methyl (CH 3 ) group at the carbon five positions of the cytosine ring by DNA methyltransferases (DNMTs) interferes with the capacity of several proteins to bind DNA. 9 Methylation in CpG-rich gene promoters serves as recognition signals for proteins mediating transcriptional repression and constitutes a mechanism for gene regulation. 10 23 and stem cell function regulation. 24 Besides, SOX17 also plays an essential role in human carcinogenesis Hypermethylation of the SOX17 promoter is correlated with poor prognosis in several cancers 25 In a previous study, we demonstrated that SOX17 is often hypermethylated and provides important prognostic information in breast cancer patients. Recent studies have shown that SOX17 is also epigenetically silenced in circulating tumor cells isolated from the peripheral blood of patients with breast or gastric cancer 26 and that such silencing can be used as a molecular diagnostic marker in stage cancer. Therefore, this study aimed to evaluate the prognostic significance of SOX17 promoter methylation in breast cancer cancer ( Fig. 1 ).
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MATERIALS AND METHODS
Study Patients
A total of 50 women with breast cancer (range 26 to 75 years) were included in this study. They were admitted at Al-Diwaniyah Teaching Hospital, Iraq, compared with 25 women as the control. We obtained plasma samples from 50 patients (breast cancer) stage II, III, IV and normal (healthy women). This study was conducted during the period from September 2016 to April 2017, were analyzed and compared to determine the tumor. Cell-free DNA was extracted blood (5 mL) was collected in K3 EDTA-containing tubes. The plasma was isolated by low-speed centrifugation: 500 × g for 10 minutes using centrifuge (Gottingen, Germany). It was (cfDNA) was isolated from 2 mL plasma using was synthesized using M-MLV cfDNA synthesis kit (Quick-cfDNATM serum and plasma DNA miniprep kit, USA) Transcript expression was evaluated using gene-specific primers unmethylation (RASSF1A)™ 57° C with the following cycling parameters: followed by 40 cycles and methy lation (RASSF1A)™ 58º C with the following cycling parameters: followed by 40 cycles the PCR products were examined by electrophoresis polymerase chain reaction (PCR) conditions were as follows: 95° C for 4 min and then 40 cycles of 95° C for 40 seconds, 58° C for 20 seconds, and 72° C for 30 seconds, with a final extension for 5 minutes at 72° C.
Also, unmethylation (SOX17) Tm (58)º C with the following cycling parameters: followed by 40 cycles and methylation (SOX17)™ (59)º C with the following cycling parameters: followed by 40 cycles the PCR products were examined by electrophoresis PCR conditions were as follows: 95° C for 4 minutes and then 40 cycles of 95° C for 40 seconds, 59° C for 20 seconds, and 72° C for 30 seconds, with a final extension for 5 minutes at 72° C.
Methylation Analysis
Genomic DNA was extracted and treated with bisulfite by using the EZ Methylation TM Kit (USA). Methylation specific PCR (MSP) primers of four selected candidate genes were prepared as described previously. 26 MSP was performed using 5 µL of modified cfDNA (USA) PCR system Furthermore, the methylation was calculated from threshold cycles (CT) values. Lastly, MSPs were analytically validated using methylated DNA by using gene-specific primers methylation (RASSAF1A) (MR) (5 ' -CCC TCC CAA ACG CCG A-3 ' ) MF (5 ' -GCT AAC AAA CGA GAA CCG-3')™ 58° C and unmethylated (57° C with the following cycling parameters: followed by 40 cycles, also MSPs were analytically validated using methylated DNA by using gene-specific primers methylation (SOX17)™ 59º C and methylated 58º C MR (5   '   -TTG CGT TAG TCG TTT GCG TTC-3   ' ) MF (5 ' -CAA AAA CGA ATC CCG TAT CCG ACG-3 ' ) with the following cycling parameters: followed by 40 cycles.
Statistical Analysis
By using Statistical Package for the Social Sciences (SPSS version 23), student test (t-test) was used for the quantitative data. The lowest level of significance was when the probability (p < 0.05). 
RESULTS
We found different methylation pattern of the
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DISCUSSION
Solid tumor release into the circulation cfDNA and CTCs which represent promising biomarkers for cancer diagnosis. Circulating tumor DNA may be studied in plasma from cancer patients by detecting tumor-specific alterations, such as genetic or epigenetic modifications association RASSEF1A. RASSEF1A promoter methylation is variably present in breast carcinoma In this study, we investigated the diagnostic performance of RASSF1A promoter methylation in cfDNA as a non-invasive marker of tumor DNA in patients We focused our attention on the methylated form of the marker since it is supposed to represent the fraction of circulating DNA deriving from the tumor by any of the hypothesized mechanisms of necrosis, apoptosis and active release. 29 We considered patients at different stages of breast cancer disease to test the reliability of the epigenetic marker under study independently from the stage of the tumor. The absolute levels of the epigenetic marker are significantly higher in breast cancer compared to controls and increases during tumor progression (from in situ to invasive and metastatic disease). To evidence, both the diagnostic and prognostic We found no significant correlation among the two biomarkers analogously to what recently reported in a study on breast cancer patients. 30 The univariate analysis performed of allowed us to assess the performance of methylated RASSF1A as a marker of tumor-related ctDNA in breast cancer for diagnostic purposes being able to discriminate the in situ and invasive breast cancer from control sand as an indicator of patients prognosis. 7 The RASSF1A family members were found to be frequently inactivated in many cancers, and such inactivation was correlated with promoter region methylation. 31, 32 The CpG island methylation of RASSF1A was reported in previous studies, 33 detected a correlation between age and methylation status. 34 On the other hand, our study found a correlation between tumor stage and differential with RASSF1A. It is well accepted that DNA promoter region methylation could result in loss and alteration of gene expression gene expression in a dose-dependent manner. Therefore, all the combined data from our study confirmed the epigenetic effect on gene expression. These study similar to the studies. 35 RASSF1A is a tumor suppressor gene silenced by promoter hypermethylation in a variety of human cancers including breast cancer.
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SOX17 promoter methylation is variably present in breast carcinoma SOX17, one of the tumor suppressor genes shown to be epigenetically silenced in CTCs of patients with breast cancer. 36 For this study, we report our findings that SOX17 was epigenetically inactivated and there are differences in levels of methylation between healthy individuals and patients with malignant conditions. We have shown that the SOX17 promoter is highly methylated in primary breast tumors, in cfDNA isolated both from patients with breast cancer and those with metastasis-verified breast cancer. These results to other studies 37 methylation status of cancerrelated genes is considered to be a promising biomarker for the early diagnosis and prognosis of tumors. This study investigated the methylation status of the SOX17 gene in breast cancer. SOX17 methylation correlated with different stage and lymph node metastasis suggested that epigenetic silencing of SOX17 may also accelerate the spread of cancer through influencing the development of an invasive and biologically aggressive phenotype and thus expedite the progression of breast cancer suggesting that SOX17 methylation in peripheral blood samples may be a good tumor marker for the diagnosis of breast cancer Thus, SOX17 promoter methylation in plasma DNA is highly specific and can provide important prognostic information for patients with breast cancer. SOX17 gene silencing due to promoter methylation may deactivate its tumor suppressor role. The tumor-suppressing function of no methylated SOX17 may be partially maintained in patients without SOX17 methylation, and this may slow the progress of tumor development.
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CONCLUSION
Our data indicate that methylation of the RASSAF1A and SOX17 genes are a frequent event in primary breast cancer and that it plays a major role in the silencing of the expression of this gene during tumor development.
